Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease

AIMS: Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspect...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Sebastian, Pilgram, Lisa, Berkowitsch, Alexander, Stecher, Melanie, Rieg, Siegbert, Shumliakivska, Mariana, Bojkova, Denisa, Wagner, Julian Uwe Gabriel, Aslan, Galip Servet, Spinner, Christoph, Luxán, Guillermo, Hanses, Frank, Dolff, Sebastian, Piepel, Christiane, Ruppert, Clemens, Guenther, Andreas, Rüthrich, Maria Madeleine, Vehreschild, Jörg Janne, Wille, Kai, Haselberger, Martina, Heuzeroth, Hanno, Hansen, Arne, Eschenhagen, Thomas, Cinatl, Jindrich, Ciesek, Sandra, Dimmeler, Stefanie, Borgmann, Stefan, Zeiher, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530317/
https://www.ncbi.nlm.nih.gov/pubmed/34673795
http://dx.doi.org/10.1371/journal.pone.0258684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530317/
https://www.ncbi.nlm.nih.gov/pubmed/34673795
http://dx.doi.org/10.1371/journal.pone.0258684

Ejemplares similares